Inogen Inc: insider trades · United States · SEC (Form 4)

About Inogen Inc

Inogen Inc. (Nasdaq: INGN) is a U.S.-based medical technology company focused on respiratory care for the homecare setting. Headquartered in Goleta, California, and listed on the Nasdaq market in the United States, Inogen is followed by global investors looking for exposure to the respiratory devices and home oxygen therapy market. The company was founded in 2001 and built its business around a straightforward proposition: offer patients a more portable, lightweight and user-friendly alternative to traditional oxygen tanks and bulkier stationary systems. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) Inogen’s core business is the design, manufacture and commercialization of portable oxygen concentrators, along with stationary oxygen solutions and related respiratory products that support chronic respiratory patients. Its portfolio includes portable concentrators under the Inogen One and Rove families, as well as adjacent offerings such as CPAP masks and other respiratory-care products. The company sells through a mix of direct-to-consumer, home medical equipment partners, prescribers and distributors, with an established U.S. base and an expanding international footprint. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) From a competitive standpoint, Inogen operates in a regulated and reimbursement-sensitive market where product portability, clinical differentiation, battery life, ease of use and access to reimbursement matter materially. Its historical edge comes from being one of the best-known names in portable oxygen concentrators, a niche where brand awareness and product credibility are important competitive assets. More recently, management has been working to diversify the portfolio beyond a single category and broaden the company’s addressable market in respiratory care. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai)) Recent developments are particularly relevant for investors. In 2025, Inogen announced a strategic collaboration with Jiangsu Yuwell Medical Equipment & Supply Co. to broaden its product portfolio, strengthen its innovation pipeline and accelerate entry into China; Yuwell also became a minority shareholder. The company also introduced new U.S. products, including the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks, and began a limited U.S. market release of the Simeox airway clearance device. Most recently, Inogen reported improving profitability trends, including year-over-year revenue growth and positive adjusted EBITDA in 2025, while reiterating its 2026 guidance and continued focus on margin and cash-flow improvement. ([investor.inogen.com](https://investor.inogen.com/news-events/press-releases/detail/256/inogen-announces-fourth-quarter-and-full-year-2025?utm_source=openai))